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Microtubules are dynamic fibrous polymers 
that are required for maintaining the physical 
property and functional plasticity of cells, as 
well as having remarkable roles in numerous 
biological processes, such as cell division and 
morphogenesis. Microtubules undergo dynamic 
inter-conversion between growth and shrinkage 
both in vivo and in vitro, which is orchestrated 
by an array of microtubule binding proteins that 
associate with microtubule lattice or ends.1 The 
lattice-associating proteins include microtubule 
stabilizers such as TPX2,2 microtubule severing 
protein katanin2 and kinesin motor CeNP-e.3 
The end-binding proteins include minus-end-
binding protein such as Nezha,4 plus-end-binding 
depolymerase such as MCAK and its associat-
ing proteins.5 Dynamic turnover of the spindle 
microtubules is a driving force for governing 
mitotic chromosome congression and segrega-
tion; however, the molecular control of the spin-
dle microtubule plasticity and dynamics is not 
well understood. To identify novel regulators 
governing spindle dynamics and chromosome 
movements, Fang and colleagues had initiated 
a genomic analysis to identify candidate mitotic 
genes in human cells based on their expression 
profiles during mitosis followed by phenotype-
based characterization using siRNA-mediated 
knock-down.6,7,8 This approach has successfully 
identified a collection of microtubule regulators 
such as HURP, Cep55 and DDA,3,9,10 which are 
essential for accurate chromosome segregation 
in mitosis.
DDA3 (differential display and is activated 
by p53) was initially identified as a down-
stream target of p53 via differential mRNA 
display approach;11 however, its precise physi-
ological function has remained elusive. Fang 
and colleagues have recently identified DDA3 
as a novel regulator of mitotic spindle essen-
tial for accurate chromosome segregation via 
analysis of genetic profiling of mitotic genes.9 
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Depletion of DDA3 perturbs chromosome 
congression and alignment at the metaphase 
equator. The DDA3-suppressed cells exhibit 
reduced inter-kinetochore tension and elon-
gated spindle length, suggesting that DDA3 
regulates microtubule dynamics. indeed, sup-
pression of DDA3 reduces the turnover rate of 
the spindle microtubule by increasing the rate 
of microtubule polymerization. The phenotype 
of DDA3-repressed cells mirrors what was 
seen in microtubule-depolymerizing Kini motor 
KiF2A-suppressed cells,12 which prompted Fang 
et al. to examine if there is a mechanistic link 
between KiF2A and DDA3. As predicted, DDA3 
interacts with the microtubule depolymerase 
KiF2A in vitro and is essential for recruiting 
KiF2A to the mitotic spindle.
To delineate the structure-functional rela-
tionship between DDA3 and KiF2A, Jang and 
Fang further analyzed the functional domains 
in DDA3 and revealed that the C-terminal 
domain of DDA3 exerts microtubule-binding 
activity in vitro and localizes to spindle in vivo.10 
Surprisingly, N-terminal domain of DDA3 car-
rying little microtubule-binding activity exhibits 
a dominant-negative effect in vivo. Strikingly, 
KiF2A failed to localize to the spindle in those 
DDA3 N-terminal overexpressing cells, sug-
gesting that the N-terminal domain of DDA3 
may bind and absorb the endogenous DDA3 
from the spindle, which mimics the phenotype 
seen in DDA3-suppressed cells. it would be of 
great interest to test whether the N-terminal 
DDA3 forms a heterodimer with endogenous 
DDA3 given the fact that N-terminal DDA3 
and endogenous DDA3 proteins distribute 
exclusively in the cytoplasm. Given the interac-
tion between KiF2A and DDA3, it would be 
of critical importance to ascertain how DDA3 
binds to the microtubule ends. interestingly, a 
brief computational analysis reveals that DDA3 
exhibits a typical eB1-binding motif, suggesting 
that DDA3 perhaps localizes to the microtu-
bule ends by which DDA3 anchors KiF2A for 
microtubule length and dynamics control. in 
fact, the mitotic distribution profile of DDA3 is 
reminiscent of a recently characterized micro-
tubule plus-end-binding protein TiP150.13 The 
finding of eB1-binding motif in DDA3 and 
possibility of DDA3 function at the plus-end 
are consistent with the early observation of 
DDA3-eB3 interaction,14 and elongated spindle 
in the absence of DDA3-KiF2A.9 in this regard, 
future experiments will be directed to ascertain 
whether DDA3 interacts with eB1-interactive 
network at the plus-ends and if suppression of 
DDA3 alters MCAK depolymerase distribution 
and function. Given the phosphorylation profile 
of DDA3 in mitosis, it would be equally impor-
tant to uncover its regulatory mechanism and 
evaluate how mitotic phosphorylation regulates 
DDA3 molecular plasticity. in any event, the 
current study by Fang and colleagues revealed 
a new class of microtubule regulators which is 
essential for mitotic chromosome plasticity. in 
sum, the findings of DDA3-KiF2A interaction 
in regulation of spindle dynamics provide a new 
direction in delineating spindle microtubule 
plasticity and dynamics.
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The Heat Shock Response (HSR) allows 
cells to combat stressful and protein-damaging 
conditions (proteotoxic stress). These stresses 
can be physical, such as heat shock or hypoxia/
ischemia or chemical, such as acidosis, ATP 
depletion or free radical generation. HSR is an 
ancient and evolutionarily conserved protective 
mechanism that involves synthesis of heat shock 
proteins (HSP), (primarily molecular chaperones 
such as Hsp90, Hsp70 and Hsp27) via activation 
of the stress-inducible transcription factor Heat 
Shock Factor 1 (HSF1). HSR is also character-
ized by attenuation of the general translation 
machinery, which contributes to minimization 
of proteotoxic stress by reducing the rate of 
newly synthesized, and potentially misfolding, 
proteins.1  Although HSF1 is itself not an onco-
gene, it organizes a broad network of cellular 
functions that act globally to support tumori-
genesis.2,3 Therefore, inhibition of HSR may 
provide a potential anti-cancer target.
in a paper published in volume 8, issue 23 
of Cell Cycle, Neznanov and co-workers have 
examined the HSR inhibitory effects of several 
anti-malarial drugs, including quinacrine (QC), 
9-aminoacridine (9AA) and emetine. These inves-
tigators hypothesized that the three drugs may 
be effective in malaria because of their shared 
ability to inhibit HSP synthesis, thereby sensitiz-
ing Plasmodium falciparum to fever induced by 
the host (e.g., heat shock). indeed, the authors 
show that QC, 9AA and emetine suppressed 
HSR. emitine is a general inhibitor of transla-
tion. However, QC inhibits NFkB-mediated 
transcription in a fashion similar to its effect 
on HSF1.4 in both cases, the drug does not 
interfere with activation, nuclear translocation 
or DNA binding of the transcription factors, 
but it effectively blocked transcription initiation. 
This suggests that nuclear localization of QC is 
important for its ability to suppress HSR. 
Although more specific than emetine, QC 
was recently reported to inhibit the phorbol 
ester induced upregulation of matrix metallo- 
proteinases MMP1 and MMP8 in leukocytes.5 
These findings indicate that the inhibitory 
effects of QC are not restricted to HSF1 and 
NFkB; nevertheless, QC may have selective 
effects on inducible transcription since the drug 
also stimulates p53-mediated transcription.4 
Neznanov and colleagues’ interesting obser-
vation raises further questions that are impor-
tant to address. For example, what is the global 
transcriptional response of QC treatment in 
tumor cells? How exactly does QC block HSF1 
transcription initiation? in most human tissues, 
all three known HSF isoforms (HSF1, HSF2 and 
HSF4) are expressed, complicating the assign-
ment of their individual functional roles and 
regulatory responses.6 For this reason yeast 
may provide a valuable system to dissect and 
better understand the inhibitory effects of QC 
on HSR.
Finally, HSF1 transcriptional activity is nor-
mally suppressed by Hsp90, and this suppres-
sion is released in the context of increased 
proteotoxic stress.7 Hsp90 also chaperones 
numerous proteins involved in carcinogenesis.8 
Several chemically distinct Hsp90 inhibitors 
have shown promising anti-tumor activity in 
vivo and one Hsp90 inhibitor, 17AAG, is cur-
rently in late stage clinical trial in HeR2-positive 
breast cancer and in multiple myeloma.9,10 
Nonetheless, Hsp90 inhibitors have proven 
to be less robust than expected in the clinic.9 
As Hsp90 pharmacologic inhibition releases 
HSF1 from chaperone-mediated suppression 
and leads to induction of HSR, the thought has 
arisen that this characteristic may provide a 
countervailing force which negatively impacts 
the broader clinical efficacy of Hsp90 inhibitors. 
Therefore, investigators are actively search-
ing for ways to blunt Hsp90 inhibitor-induced 
HSF induction. The current data provided by 
Neznanov et al. supply a strong justification for 
further evaluating the anticancer properties 
of QC or similar compounds, especially in the 
context of Hsp90 inhibition. 
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Despite its relatively low incidence rate, 
ovarian cancer is an extremely lethal disease. 
it is the fifth leading cause of cancer death in 
women and is the most lethal gynecological 
malignancy. The reason for this is mainly because 
in its early stages, ovarian cancer has few, rather 
minor symptoms and, when diagnosed, the dis-
ease is often extensive, which current therapies 
have little effect on. However, the early events 
associated with the pathogenesis of ovarian 
cancer are poorly understood.
in order to elucidate the underlying disease 
mechanisms, the development of suitable in 
vitro systems and mouse models that can faith-
fully reproduce the pathological characteristics 
of human ovarian carcinomas are important. 
One of the greatest challenges in diagnosis 
and treatment of ovarian cancer is its het-
erogenous nature. Serous carcinomas are the 
most common subtype of ovarian carcinoma, 
accounting for approximately 70% of all ovarian 
cancer. They are rarely confined to the ovaries 
at diagnosis and for almost 90% of stage iii or iv 
tumors. The rapid and distant metastatic spread 
and progression to chemoresistance account 
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for an exceptionally high percentage of deaths 
of patients.1
in the last issue of Cell Cycle, Zheng et 
al. provide experimental evidence for normal 
human OSe to undergo neoplastic progression.2 
Histopathologic examination of these tumors 
revealed papillary carcinoma that resembles 
human papillary serous ovarian carcinoma.2 
Specifically, these authors, which was shown pre-
viously to transform human OSe using a defined 
set of genetic manipulations including the Sv40 
T/tag, hTeRT and RAS,3 were able to transfect 
these cells with HeR2/neu to give rise to papil-
lary differentiation. interestingly, the develop-
ment of tumors with papillary differentiation 
relies not only on specific genetic modifications 
but also on the tumor microenvironment. 
There are few animal models, such as mice, 
rats and hens, that develop ovarian tumors 
spontaneously.4 However, the low incidence 
and the length of time required for the devel-
opment of these tumors have limited their 
use for studying the biology of ovarian cancer. 
induced tumor models may circumvent some 
of these problems. in this paper, Zheng et 
al. have elegantly shown us that overexpres-
sion of selected oncogene can cause papillary 
carcinoma that closely resemble the human 
disease histopathologically. This effect seems 
to be specific to the choice of oncogene as 
in their previous publication, tumors derived 
from RAS-transformed cells remained largely 
undifferentiated or poorly differentiated. K-RAS 
mutations are only rarely seen in ovarian serous 
carcinomas, whereas gene amplification and 
overexpression of HeR-2/neu are more com-
mon.5,6 This also strongly implies that malignant 
transformation and histological differentiation 
are controlled via independent pathways. 
While it is widely believed that ovarian 
carcinoma develops de novo from the OSe, this 
view has recently been questioned. Alternative 
cellular origins such as the fallopian tube have 
been proposed based on the discovery that 
dysplastic lesions and in situ carcinomas in the 
fallopian tube fimbria, but not OSe, in most 
cases of prophylactic salphingo-oophorectomy 
specimens of BRCA mutation carriers, and that 
women with ovarian serous carcinomas also 
harbor tubal intraepithelial carcinomas with 
the presence of identical p53 mutations.7-9 in 
this connection, it is interesting to see that the 
work of Zheng et al. shows normal human OSe 
can undergo neoplastic progression to papillary 
carcinoma when modified with specific genetic 
elements. The presence of Sv40 T/tag positive 
tumor cells is in support of tumors originating 
at the transformed OSe. The introduction of 
various other genetic alterations in the OSe 
has also been shown to give rise to ovarian 
carcinoma in other mouse models.4 However, 
most of the tumors developed in these mod-
els were poorly differentiated, suggesting that 
mechanisms other than genetic alterations may 
control the histological differentiation.
What is also attractive about Zheng et 
al. study is the cell line can only develop 
into papillary differentiation in a peritoneal 
microenvironment, which closely duplicates the 
well-established progression of ovarian can-
cer. Although carcinogenesis has long been 
considered a cell autonomous event in which 
progressive genetic alterations transform cells 
independent of external cues, there is increasing 
evidence to suggest that the tumor microen-
vironment plays an important role in cancer 
development and progression.10 Clearly, there 
must be something special about the interac-
tion between ovarian carcinoma and peritoneal 
epithelium that promotes the neoplastic growth 
and differentiation of the transformed OSe. 
indeed, human peritoneal cells have been shown 
to release regulatory chemokines, cytokines 
and growth factors in response to inflammation 
induced by epithelial ovarian cancer implanta-
tion.11 it will be interesting to identify those 
cytokines and factors in the peritoneal microen-
vironment that are critical to papillary growth 
and differentiation. 
in summary, these new findings suggest an 
attractive model of papillary differentiation to 
explain the importance of tumor microenviron-
ment on the genetic contributions in ovarian 
tumor development. This provides a preclinical 
model to test developing therapeutics and will 
also allow analysis of ovarian tumor progression 
at the cellular and molecular levels.
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Taxonomy based on genome-wide molecu-
lar portraits of tumors has become a mainstay 
of personalized medical care for cancer patients. 
Microarray-based multigene assays, such as 
Mammaprint® or MapQuant® designed to 
individualize treatment for patients with breast 
cancer, are already integrated in clinical prac-
tice.1 However, using whole tumor molecular 
signatures as prognostic or predictive markers 
might be in contradiction with the emerging 
cancer stem cell concept.
This concept is based on the existence of a 
subpopulation of undifferentiated cancer cells 
responsible for tumor initiation, maintenance 
and therapeutic resistance, the cancer stem 
cells (CSCs).2-4 The number of stem cells within 
a tumor is thought to be low as compared to 
the bulk of their cancer cell progeny. Thus, the 
scarcity of the CSC population might not be 
reflected in the molecular portrait established 
on the global cancer cell population.
To combine molecular portraits of tumor 
and the CSC concept many groups have 
sought to determine whether the presence of 
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molecular imprints of stemness [embryonic 
stem cells (eSC) or adult tissue-specific stem 
cells signatures] in tumors might be detected 
and whether they could represent accurate 
prognostic markers.5-7 in this issue, using molec-
ular signatures enrichment analyses, Hussenet 
et al. demonstrates that an eSC-like molecular 
phenotype is enriched in tumor compared to 
normal tissue but is not different between CSCs 
and non-CSCs. interestingly, several studies have 
described an association between an eSC-like 
phenotype and poor prognosis in various types 
of cancer (including breast, lung, bladder and 
brain tumors). These observations are inter-
preted by Hussenet et al. as a hallmark of poor 
differentiation rather than a surrogate of cancer 
stem cell activity, as suggested by similar stud-
ies.5-7 Thus, the eSC-like signature in cancers is 
more likely the results of re-activation of an 
eSC-like phenotype during the course of tumor 
progression rather than an inherited phenotype 
from a cell-of-origin. Consequently, this eSC-like 
signature failed to link CSCs biology with the 
whole molecular portrait of the tumor. 
The question of stemness signature within 
a tumor as a valid molecular marker for cancer 
prognosis remains open. in other words, does 
the number or quality of CSCs reflect cancer 
clinical evolution? CD44+CD24- phenotype 
and ALDH1 expression, both associated with 
tumor-initiating cells, have been investigated as 
prognostic markers. Only the presence ALDH1 
positive cells is associated with poor clinical 
outcome.8,9 even though these data appear 
contradictory, one can expect that a more 
complete approach based on genome-wide 
profiling of CSCs might be more successful for 
prognostic prediction. exploring this approach, 
Hussenet and colleagues show that a normal 
adult tissue-specific stem cell molecular pheno-
type, previously defined, is enriched in epithelial 
cancer stem cells compared to non tumori-
genic cancer cells. Moreover, they provide evi-
dence that enrichment in CSC-signatures is 
correlated with poor prognosis in breast and 
lung carcinomas. 
The development of CSC molecular portraits 
is promising in translating the CSC concept to 
clinical practice, even though it remains critical 
to further validate the subsequent signatures at 
the functional level. Moreover, characterization 
of CSC genomic profiles will contribute to open 
the Pandora box of CSC targeted therapies.
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Development of a multicellular organism 
involves coordinated cellular division and differ-
entiation programs to generate the appropriate 
cell types and tissues. This complex orchestra-
tion depends on gene regulatory pathways that 
function in the right place and at the right time. 
Genetic screens in C. elegans identified a series 
of genes that regulate developmental timing.1 
Mutant worms that reiterate or skip earlier cell 
fates are classified as heterochronic, or devel-
opmental timing, mutants because their cell 
lineages are temporally transformed.2 Several 
genes in this pathway, including lin-14, lin-29 
and hbl-1, encode transcription factors and 
potentially act as master regulators in multiple 
cell types to promote gene expression patterns 
appropriate for specific stages in development. 
Hence, identification of the genes under the 
control of these transcription factors will help 
elucidate the networks that drive cellular pro-
gression in tune with the developmental clock.
in a new study by Niwa et al., Cell Cycle 2009, 
dozens of genes affected by hbl-1 activity were 
identified in developing worms.3 The hunchback-
like-1 (hbl-1) gene in C. elegans is the homolog 
of the Drosophila melanogaster hunchback (hb) 
transcription factor.4 Hb was first identified 
in Drosophila as a member of the gap class 
of segmentation genes and is a key regulator 
of embryonic segmentation, pattern formation 
and neuroblast identity. in Drosophila, hb binds 
to well characterized A-rich DNA motifs and 
can function as a transcriptional activator or 
repressor depending on its concentration and 
interaction partners.5 Homologs of hunchback 
are present from worms to humans, but the 
function of these genes in animal develop-
ment has not been deeply investigated beyond 
ecdysozoans. 
The C. elegans homolog of hunchback, hbl-1, 
is expressed during embryogenesis and is 
required for later larval development, but not 
for early pattern formation.4,6,7 Hbl-1 was identi-
fied as a member of the heterochronic pathway 
because mutations in this gene result in the 
precocious differentiation of hypodermal cells.6,7 
expression of hbl-1 is observed in multiple 
embryonic cell lineages but becomes predomi-
nantly neuronal after hatching.4 During larval 
development, temporal down-regulation of hbl-1 
in hypodermal and neuronal cells is mediated at 
least in part by the miRNA pathway. The let-7 
miRNA and its related “sister” miRNAs, mir-48, 
mir-241 and mir-84, regulate hbl-1 expression 
via multiple complementary sites in its 3’UTR.6-8 
Recently, hbl-1 and let-7 were reported to be in 
a negative feedback loop.9 This model is based 
on evidence that transcription of let-7 miRNA 
is repressed by HBL-1 protein in hypoder-
mal cells until the let-7 sister miRNAs inhibit 
hbl-1 expression during the transition from 
the second to third larval stages.8,9 The result-
ing increase in let-7 miRNA can then bolster 
repression of hbl-1 by the miRNA pathway.6-9
The study by Niwa and colleagues demon-
strates that let-7 is probably just one of many 
transcriptional targets of hbl-1 in developing 
worms.3 To detect genes that respond to HBL-1 
protein, the authors induced expression in live 
worms using a heat-shock promoter fused 
to the hbl-1 gene. A pulse of hbl-1 expression 
during the last larval stage (L4) was sufficient 
to induce heterochronic defects, prompting 
the investigation of target genes that might 
contribute to the phenotypes. Using microar-
ray analyses, the authors detected significant 
up and down regulation of 26 and 53 genes, 
respectively, in worms induced to express hbl-1 
during L4. This genome wide analysis revealed 
a common A-rich motif upstream of both the 
positively and negatively regulated sets of genes. 
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Remarkably, this motif is comparable to the 
well-established Hunchback recognition site in 
Drosophila.10 
By investigating potential genetic interac-
tions between hbl-1 and each of the genes 
mis-regulated upon induction of HBL-1 protein, 
the authors identified sym-1, which encodes 
a protein with multiple leucine-rich repeats.3 
interestingly, the genetic data indicate that hbl-1 
directs opposite cellular fates through sym-1 
during the larval and adult stages, inhibiting then 
promoting differentiation of hypodermal cells. 
This complexity may be expected if regulation 
by hbl-1 is modulated by graded HBL-1 levels 
and combinatorial actions with other transcrip-
tion factors, as is the case in Drosophila.5 
The identification of potential direct targets 
of hbl-1 transcriptional regulation, including a 
genetically validated target, is an important con-
tribution towards understanding the common 
and distinct pathways controlled by hunchback 
homologs across species. The finding that simi-
lar numbers of genes positively and negatively 
responded to ectopic hbl-1 expression sug-
gests that this transcription factor may act 
as an activator or repressor, although further 
experiments are needed to determine direct 
versus indirect effects. Additionally, all of the 
mis-regulated genes were found to contain 
A-rich motifs in their promoter regions, indicat-
ing that context and other factors may govern 
whether hbl-1 activates or represses specific 
targets. Considering the spatially and temporally 
regulated expression pattern of HBL-1 protein, 
future studies may reveal entirely different 
networks of genes under the control of this 
dynamic transcription factor.
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Circadian rhythms: Phosphorylating the CLOCK
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The molecular circadian clock is a cell-
autonomous system organized to create a 
conserved transcriptional-based negative feed-
back loop. This feedback loop is initiated when 
a transcription factor complex (positive arm) 
induces the expression of negative elements 
which, after a time-delay, feed back to inhibit 
the positive arm. The kinetic properties of 
circadian systems are set through post-trans-
lational modifications (PTMs) acting on nearly 
every component.1 Phosphorylation is gener-
ally regarded as the PTM primarily responsible 
for setting the 24-hour period length through 
altering the stability or accessibility of the 
negative (repressor) complex.  While a number 
of studies have focused on comprehensive dis-
section of these negative element PTMs,2-4 the 
molecular rhythms community has just begun 
to dig into the regulation and function of PTMs 
in the positive arm. in a previous issue of Cell 
Cycle, Spengler et al.5 fill in some of the story by 
investigating the role of phosphorylation on the 
transcription factor CLOCK in the mammalian 
circadian system and present data on its pos-
sible regulation by the GSK-3b kinase.
CLOCK forms a heterodimeric complex 
with another transcription factor, BMAL1, and 
together they regulate expression of circadianly 
regulated genes.  Both trigger each other’s 
phosphorylation but little is known about the 
function of these PTMs. The authors have taken 
a bioinformatic approach to identify potential 
phosphorylation sites on CLOCK, narrowing 
down the possibilities within the 885-residue 
protein to focus on a region encompassing 
36 conserved residues, 425–461, containing 
predicted kinase targets. CLOCK proteins har-
boring serine/threonine to alanine mutations in 
this region result in decreased phosphorylation 
and an increase in protein stability, thus defin-
ing a discreet region on CLOCK important 
for regulated turnover, termed a “phospho-
degron.” The authors show that these phopho-
deficient mutants still interact with BMAL1 and 
that BMAL1-mediated degradation of CLOCK 
requires the phospho-degron. Circadian physiol-
ogy is also impacted as the mutant CLOCK pro-
teins have attenuated transcriptional activity and 
an apparent phase delay in synchronized cells. 
Previously a mass-spectrometry based study 
had shown that S427, within the phospho-degron, 
is phosphorylated in vivo;6 however, that study 
did not establish function to the site. Spengler 
et al. further focus on two residues, including 
the in vivo phosphorylated S427, and S431. 
Mutation of S431A almost completely blocks all 
BMAL1-dependent CLOCK phosphorylation, 
while S427 is one of two predicted GSK-3b tar-
get sites within the phospho-degron. These data 
led the authors to hypothesize a conserved role 
for GSK-3b in regulating CLOCK specifically at 
S427, with S431 acting as its priming site. Along 
these lines, they present compelling evidence 
that GSK-3b can phosphorylate CLOCK in 
vitro and manipulation of upstream activators/
inhibitors of GSK-3b predictably alters CLOCK 
phosphorylation and stability.  Unfortunately, 
S427A and S431A mutations were not assessed 
individually for CLOCK stability, and were 
not included in the mutant strains when the 
authors looked at BMAL1-dependent CLOCK 
degradation or the circadian phase delay. if the 
proposed model is that GSK-3b mediates these 
clock effects specifically through S427 it would 
be interesting to look at S427A and S431A using 
the same conditions in order to determine if 
they impact CLOCK functions.
While this study defines a new region impor-
tant for proper phosphorylation and function of 
CLOCK it also raises a few interesting questions. 
For instance, why would reduced phosphoryla-
tion and increased stability lead to an attenua-
tion of transcriptional activity? One possibility 
is that phosphorylation is structurally required 
for CLOCK/BMAL1 promoter occupancy or, 
as the authors make the case, that there is an 
intermediate, unstable, phosphorylated form 
more transcriptionally active:  such a model has 
recently been suggested based on data from 
fungal circadian oscillators7 whose molecular 
architecture is quite similar to the mamma-
lian clock studied here. Additionally, given that 
small molecule inhibitors of GSK-3b specifically 
decrease period in cycling mammalian cells,8 it 
is interesting that in this study the proposed 
role of GSK-3b is in promoting degradation 
of CLOCK. The authors suggest that reduc-
tion of CLOCK phosphorylation results in the 
observed phase delay, through longer protein 
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half-life. This is perhaps opposite to what one 
might expect when inactivation of the respon-
sible kinase leads to period decreases. However, 
here the authors are looking at one specific 
target, CLOCK, which may not be the only 
circadian protein regulated by GSK-3b. While 
further work will be needed to understand how 
GSK-3b activity affects other kinetic parameters 
of the circadian clock, Spengler et al. have taken 
an important first step in the analysis.
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